Expression of STAT5A in cancer - Staining overview

The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with high, medium, low or not detected (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.

The cancers can be ordered histologically or alphabetically.

For each cancer, the staining for each available antibody is reported as the fraction of samples with antibody staining level high, medium, low or not detected (as described by the color-coding scale in the box to the right). The length of the bar represents the number of patient samples analyzed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.

At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the literature conformity for the staining pattern revealed by that specific antibody.

Antibody HPA027873

Antibody HPA042128

Antibody HPA049883

Antibody HPA051156

Antibody CAB003860

Tissue

Antibody staining

Summary

Cases of lymphomas displayed moderate to strong cytoplasmic and nuclear staining. Remaining cancers were in general weakly stained or negative.

Cases of breast cancers showed weak to moderate cytoplasmic staining. Remaining cancers were generally negative.

Several hepatocellular carcinomas, urothelial cancers and melanomas along with a few gliomas and colorectal cancers displayed weak to moderate cytoplasmic and/or nuclear positivity. Cases of lung adenocarcinomas showed moderate to strong staining. Remaining cancers were negative.

Most cancers showed weak to moderate cytoplasmic immunoreactivity. Carcinoids, liver, prostate and skin cancers along with most lymphomas, testicular and lung cancers were negative.

Strong cytoplasmic and nuclear immunoreactivity was observed in lymphomas and cases of melanomas and breast cancers. Remaining cancers were in general negative.

Literature conformity

Consistent with extensive gene/protein characterization data

Partly consistent with extensive gene/protein characterization data

Partly consistent with gene/protein characterization data

Partly consistent with extensive gene/protein characterization data

Consistent with extensive gene/protein characterization data

Level of antibody staining/expression

High
Medium
Low
Not detected

The Human Protein Atlas project is funded by the Knut & Alice Wallenberg foundation.